Five takeaways:
1. First-quarter net sales hit $105.6 million, up 1 percent year over year.
2. Spine implant sales jumped 12.1 percent, to $25.7 million, while biologics fell 1.8 percent to $13.7 million.
3. Global spine sales were flat at $82.3 million, and global orthopedic sales were up 3.3 percent, to $23.3 million.
4. Orthofix reported a $5.8 million net loss for the quarter, and gross profit dropped to $1.7 million.
5. Orthofix expects 2021 net sales to reach $455 million to $465 million, a 12 percent to 14.4 percent increase over 2020.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.